Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.
Also called NCT01722214
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 107 participants
- Sponsor
- Registry
-
NCT01722214
-
- Other papers using this trial's data
- TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT01722214. Randomized; triple masking; primary purpose prevention. Start 2012-11 (registry gives no type); primary completion 2015-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis
- Condition
- Psoriasis
- Condition
- Vascular Inflammation
- Condition
- Coronary Atherosclerosis
- Intervention (Biological)
- Adalimumab
- Intervention (Other)
- Placebo
- Lead sponsor
- Innovaderm Research Inc.
- Collaborator
- Abbott
- Collaborator
- Montreal Heart Institute
Record details
- Record id
cardio:ct-nct01722214- Content hash
4959c083ed961ec6accd3180dfec1dcecdf2a12c78b77da11357882bcf96986f